[go: up one dir, main page]

CL2019000914A1 - Composiciones de combinaciones que comprenden agonistas de fxr para tratar o prevenir una enfermedad o un trastorno fibrótico o cirrótico. - Google Patents

Composiciones de combinaciones que comprenden agonistas de fxr para tratar o prevenir una enfermedad o un trastorno fibrótico o cirrótico.

Info

Publication number
CL2019000914A1
CL2019000914A1 CL2019000914A CL2019000914A CL2019000914A1 CL 2019000914 A1 CL2019000914 A1 CL 2019000914A1 CL 2019000914 A CL2019000914 A CL 2019000914A CL 2019000914 A CL2019000914 A CL 2019000914A CL 2019000914 A1 CL2019000914 A1 CL 2019000914A1
Authority
CL
Chile
Prior art keywords
treat
prevent
cirrhotic
fibrotic
compositions
Prior art date
Application number
CL2019000914A
Other languages
English (en)
Inventor
Andreas Bauer
Patrick Mueller
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2019000914A1 publication Critical patent/CL2019000914A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCIÓN PROPORCIONA COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN UN AGONISTA DEL RECEPTOR FARNESOIDE X (FXR) Y OTRO AGENTE TERAPÉUTICO, EN PARTICULAR, PARA TRATAR O PREVENIR ENFERMEDADES O TRASTORNOS HEPÁTICOS.
CL2019000914A 2016-10-05 2019-04-04 Composiciones de combinaciones que comprenden agonistas de fxr para tratar o prevenir una enfermedad o un trastorno fibrótico o cirrótico. CL2019000914A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662404303P 2016-10-05 2016-10-05

Publications (1)

Publication Number Publication Date
CL2019000914A1 true CL2019000914A1 (es) 2019-06-14

Family

ID=60262958

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000914A CL2019000914A1 (es) 2016-10-05 2019-04-04 Composiciones de combinaciones que comprenden agonistas de fxr para tratar o prevenir una enfermedad o un trastorno fibrótico o cirrótico.

Country Status (15)

Country Link
US (1) US20190231770A1 (es)
EP (1) EP3522883A1 (es)
JP (1) JP2019530696A (es)
KR (1) KR20190062501A (es)
CN (1) CN109789119A (es)
AR (1) AR109809A1 (es)
AU (1) AU2017339826A1 (es)
BR (1) BR112019005985A2 (es)
CA (1) CA3039283A1 (es)
CL (1) CL2019000914A1 (es)
IL (1) IL265817A (es)
MX (1) MX2019003889A (es)
RU (1) RU2019113150A (es)
TW (1) TW201815420A (es)
WO (1) WO2018065902A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019053582A1 (en) * 2017-09-13 2019-03-21 Novartis Ag COMBINATIONS HAVING FXR AGONISTS
US20220047553A1 (en) * 2018-09-18 2022-02-17 Metacrine, Inc. Farnesoid x receptor agonists for the treatment of disease
AU2020312734B2 (en) * 2019-07-18 2025-11-20 Enyo Pharma Improved treatment using EYP001
JP2022548617A (ja) * 2019-09-19 2022-11-21 ノバルティス アーゲー Ｆｘｒアゴニストを含む処置
JP2022550312A (ja) * 2019-09-30 2022-12-01 ノバルティス アーゲー Ｆｘｒアゴニストの使用を含む処置
CN113244281B (zh) * 2021-06-09 2022-11-01 贵州医科大学 黄水枝醇提物在制备治疗或保护、调节肝纤维化疾病药物中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053056B2 (en) 1998-07-02 2006-05-30 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6544951B2 (en) 1998-07-02 2003-04-08 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6197750B1 (en) 1998-07-02 2001-03-06 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6559304B1 (en) 1998-08-19 2003-05-06 Vertex Pharmaceuticals Incorporated Method for synthesizing caspase inhibitors
US6201118B1 (en) 1998-08-19 2001-03-13 Vertex Pharmaceuticals Inc. Process for forming an N-acylated, N,N-containing bicyclic ring from piperazic acid or an ester thereof especially useful as an intermediate in the manufacture of a caspase inhibitor
PT1163208E (pt) 1999-08-06 2004-08-31 Vertex Pharma Inibidores de caspase e as suas utilizacoes
US6790989B2 (en) 2000-01-13 2004-09-14 Idun Pharmaceuticals, Inc. Inhibitors of the ICE/ced-3 family of cysteine proteases
PL201081B1 (pl) 2000-03-29 2009-03-31 Vertex Pharma Związek karbaminianowy, zawierająca go kompozycja farmaceutyczna i jego zastosowania
AP2002002407A0 (en) 2000-05-23 2002-03-31 Vertex Pharma Caspase inhibitors and uses thereof.
DE60131160T2 (de) 2000-06-07 2008-08-07 Vertex Pharmaceuticals Inc., Cambridge Caspase-inhibitoren und ihre verwendungen
JP2004509120A (ja) 2000-09-13 2004-03-25 バーテックス　ファーマシューティカルズ　インコーポレイテッド カスパーゼ阻害剤およびそれらの用途
US6665495B1 (en) 2000-10-27 2003-12-16 Yotta Networks, Inc. Non-blocking, scalable optical router architecture and method for routing optical traffic
MXPA03009647A (es) 2001-04-19 2004-01-29 Vertex Pharma Heterociclildicarbamidas como inhibidores de caspasa.
JP4428926B2 (ja) 2001-05-23 2010-03-10 バーテックス ファーマシューティカルズ インコーポレイテッド カスパーゼインヒビターおよびそれらの使用
US7410956B2 (en) 2002-02-11 2008-08-12 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs
US7553852B2 (en) 2002-06-28 2009-06-30 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
US7612091B2 (en) 2002-12-20 2009-11-03 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
PE20050159A1 (es) 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
KR100594544B1 (ko) 2003-08-27 2006-06-30 주식회사 엘지생명과학 이소옥사졸린 구조를 갖는 캐스파제 저해제
NZ549665A (en) 2004-02-27 2010-09-30 Vertex Pharma Caspase inhibitors and uses thereof
JP2005319019A (ja) 2004-05-07 2005-11-17 Bridgestone Sports Co Ltd ゴルフクラブヘッド
MX2007000490A (es) 2004-07-12 2007-06-11 Idun Pharmaceuticals Inc Analogos de tetrapeptido.
AU2007330478B2 (en) 2006-12-06 2011-09-08 Conatus Pharmaceuticals, Inc. Crystalline forms of ( 3 S ) -3- [N- (N' - (2-tert-butylphenyl) oxamyl) alaninyl] amino-5- (2 ', 3 ', 5 ', 6 ' -tetrafluorophenoxy) -4-oxopentanoic acid
WO2010120880A1 (en) * 2009-04-14 2010-10-21 Vertex Pharmaceuticals Incorporated Treatment of liver diseases with a caspase inhibitor
KR102350357B1 (ko) * 2013-11-05 2022-01-14 노파르티스 아게 파르네소이드 x 수용체의 조정을 위한 조성물 및 방법
KR20170095965A (ko) * 2014-12-18 2017-08-23 노파르티스 아게 간 및 위장 질환의 치료에 사용하기 위한 fxr 효능제로서의 아자비시클로옥탄 유도체
US20190022043A1 (en) * 2015-12-31 2019-01-24 Conatus Pharmaceuticals Inc. Methods of using caspase inhibitors in treatment of liver disease
US11110083B2 (en) * 2016-02-22 2021-09-07 Novartis Ag Methods for treating liver disorders using FXR agonists

Also Published As

Publication number Publication date
JP2019530696A (ja) 2019-10-24
RU2019113150A (ru) 2020-11-06
WO2018065902A1 (en) 2018-04-12
IL265817A (en) 2019-06-30
KR20190062501A (ko) 2019-06-05
MX2019003889A (es) 2019-08-12
BR112019005985A2 (pt) 2019-06-25
EP3522883A1 (en) 2019-08-14
TW201815420A (zh) 2018-05-01
CA3039283A1 (en) 2018-04-12
AU2017339826A1 (en) 2019-04-04
US20190231770A1 (en) 2019-08-01
AR109809A1 (es) 2019-01-23
CN109789119A (zh) 2019-05-21

Similar Documents

Publication Publication Date Title
CL2019000914A1 (es) Composiciones de combinaciones que comprenden agonistas de fxr para tratar o prevenir una enfermedad o un trastorno fibrótico o cirrótico.
CL2018002727A1 (es) Medicina obtenida mediante la combinación de agonista fxr y arb
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
EA202190661A1 (ru) Агонисты фарнезоидного х-рецептора для лечения заболевания
MX2018003388A (es) Agonistas del receptor farnesoide x y usos de los mismos.
MX2022007989A (es) Composiciones y metodos para tratar pterigion.
CL2019000625A1 (es) Combinación de agonistas de fxr.
BR112018005777A2 (pt) anticorpo, polinucleotídeo, vetor de expressão, células hospedeiras, método para produzir um anticorpo de interesse ou um fragmento do mesmo composição farmacêutica, e, uso de pelo menos um anticorpo
MX2017005875A (es) Metodos para tratar enfermedades oculares.
MX382033B (es) Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
BR112016025312A2 (pt) variantes de anticorpo, anticorpo anti-fator d, formulação farmacêutica, dispositivo de distribuição, utilização da formulação e de uma composição, composição e método de tratamento de uma desordem
MX2016010854A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de un antagonista de il-4r.
SI3377637T1 (sl) Sestavki za uporabo pri postopkih za zdravljenje ran, motenj in bolezni kože
BR112017002637A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
MX2018005194A (es) Proteinas de fusion fgf21 de accion prolongada y composicion farmacuetica que comprende las mismas.
EA201890891A1 (ru) Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
MX2016011667A (es) Composiciones topicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad.
MX382757B (es) Inhibidor del sistema complemento de ornithodoros moubata para utilizarse en el tratamiento de enfermedades mediadas por el sistema complemento en pacientes con polimorfismo de c5.
MX380531B (es) Agonistas del receptor activado por proliferador de peroxisoma (ppar), compuestos, composiciones farmacéuticas y métodos para usar los mismos.
BR112018069682A2 (pt) métodos de tratamento para doenças colestáticas e fibróticas
ECSP19000169A (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
MX2022004382A (es) Metodos para promover la produccion de scfa por microbiota intestinal.
MX2018002298A (es) Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.